Jumpcode Genomics

Executive Summary

Jumpcode Genomics is a life science tools company that has developed CRISPRclean, a proprietary technology leveraging programmable endonucleases to selectively deplete abundant, uninformative nucleic acid sequences (e.g., ribosomal RNA, host genomic DNA) from samples prior to next-generation sequencing (NGS). By removing these dominant sequences, CRISPRclean enriches for the relevant genetic material—such as pathogen DNA in infectious disease samples, or transcripts in single-cell RNA-seq—resulting in significantly higher sequencing depth, lower costs, and improved detection sensitivity. The technology addresses a critical bottleneck in NGS workflows, where up to 90% of sequencing reads can be wasted on unwanted sequences, limiting the utility of sequencing in applications like metagenomics, liquid biopsy, and transcriptomics. Founded in 2017 and headquartered in San Diego, Jumpcode Genomics targets high-growth markets including infectious disease diagnostics, microbiome research, and single-cell analysis. Its approach offers a simpler, more cost-effective alternative to existing depletion methods, enabling researchers and clinicians to glean deeper insights from limited samples. With the global NGS market expanding rapidly and increasing demand for targeted sequencing, Jumpcode is well-positioned to capture value through product sales, partnerships, and potential expansion into clinical diagnostics. The company's technology has broad applicability and could become a standard sample preparation tool in both research and clinical settings.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of a CRISPRclean-based kit for infectious disease detection65% success
• H1 2027Strategic partnership with a major sequencing platform provider (e.g., Illumina or Oxford Nanopore)50% success